<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03096223</url>
  </required_header>
  <id_info>
    <org_study_id>4083-004</org_study_id>
    <nct_id>NCT03096223</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of KHK4083 in Subjects With Atopic Dermatitis</brief_title>
  <official_title>A Phase 1, Open-Label, Multiple-Dose Study of KHK4083 in Subjects With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and tolerability of multiple&#xD;
      intravenous (IV) infusions of KHK4083 in subjects with moderate or severe atopic dermatitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 10, 2017</start_date>
  <completion_date type="Actual">February 7, 2018</completion_date>
  <primary_completion_date type="Actual">February 7, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs) or drug-related TEAEs and their nature</measure>
    <time_frame>Up to 22 weeks post drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum KHK4083 concentration</measure>
    <time_frame>Up to 22 weeks post drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>Up to 22 weeks post drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (tmax)</measure>
    <time_frame>Up to 22 weeks post drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>Up to 22 weeks post drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-KHK4083 antibody production</measure>
    <time_frame>Up to 22 weeks post drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>KHK4083</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KHK4083</intervention_name>
    <description>IV administration</description>
    <arm_group_label>KHK4083</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntary written informed consent to participate in the study&#xD;
&#xD;
          2. Atopic dermatitis diagnosed according to the Definition and Diagnostic Criteria for&#xD;
             Atopic Dermatitis (Guidelines for Management of Atopic Dermatitis 2016) established by&#xD;
             the Japanese Dermatological Association&#xD;
&#xD;
          3. Moderate or severe (≥4.5) symptoms of atopic dermatitis at screening, according to the&#xD;
             Rajka &amp; Langeland Severity Index&#xD;
&#xD;
          4. Investigator Global Assessment(IGA) ≥3 (moderate) at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any of the following clinically significant concurrent illnesses:&#xD;
&#xD;
               -  Type 1 diabetes&#xD;
&#xD;
               -  Poorly controlled type 2 diabetes (HbA1c &gt;8.5%)&#xD;
&#xD;
               -  Congestive heart failure (class II to IV of the New York Heart Association&#xD;
                  classification)&#xD;
&#xD;
               -  Myocardial infarction within 1 year&#xD;
&#xD;
               -  Unstable angina pectoris within 1 year&#xD;
&#xD;
               -  Poorly controlled hypertension (systolic pressure &gt;150 mm Hg or diastolic&#xD;
                  pressure &gt;90 mm Hg at screening)&#xD;
&#xD;
               -  Severe chronic lung diseases requiring oxygen therapy&#xD;
&#xD;
               -  Multiple sclerosis or other demyelinating diseases&#xD;
&#xD;
               -  Active malignancies, or onset or a history of treatment of malignancies within 5&#xD;
                  years prior to informed consent (except for resected or surgically cured&#xD;
                  epithelial carcinoma of the uterine cervix, cutaneous basal cell carcinoma,&#xD;
                  cutaneous squamous cell carcinoma, or ductal carcinoma)&#xD;
&#xD;
          2. Current or past history of clinically significant cardiovascular, liver, renal,&#xD;
             respiratory, hematologic, central nervous system, psychiatric, or autoimmune&#xD;
             diseases/disorders other than those in 1)&#xD;
&#xD;
          3. Alcohol dependence, or drug dependence or a positive result for any of the drug abuse&#xD;
             test items&#xD;
&#xD;
          4. Past or current history of drug allergy&#xD;
&#xD;
          5. Any clinically significant infection requiring hospitalization or IV administration of&#xD;
             antibiotics within 8 weeks prior to pre-enrollment&#xD;
&#xD;
          6. Any planned surgical treatment during the study&#xD;
&#xD;
          7. Any skin disease that may affect the clinical symptom assessment&#xD;
&#xD;
          8. Pregnant or lactating women, or women willing to have a child during the study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Closed information</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>March 23, 2017</study_first_submitted>
  <study_first_submitted_qc>March 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2017</study_first_posted>
  <last_update_submitted>March 25, 2018</last_update_submitted>
  <last_update_submitted_qc>March 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>KHK4083</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

